Is Gilead Sciences Stock Outperforming the Dow?

Core Insights - Gilead Sciences, Inc. is a leading biopharmaceutical company known for its innovations in treating complex diseases, particularly in HIV/AIDS, hepatitis B and C, and COVID-19, with a focus on oncology and inflammatory diseases as future growth areas [1][2] Financial Performance - Gilead has a market capitalization of $155.4 billion, placing it in the large-cap category, with a strong product portfolio and revenue consistency justifying its valuation [2] - GILD stock has shown impressive performance, with a year-to-date increase of 35.6% and a 52-week surge of 38.9%, significantly outperforming the Dow Jones Industrial Average [4] - The stock price reached a high of $128.70 on November 11, and has increased by 9.2% over the past three months, indicating strong investor interest [3][4] Earnings Report - In Q3 2025, Gilead reported a revenue increase of 3% year-over-year, totaling $7.8 billion, driven primarily by its HIV franchise and liver disease therapies [5]